Rinvoq (upadacitinib) / AbbVie - LARVOL DELTA

Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review. (PubMed, Arthritis Care Res (Hoboken)) - "There is heterogeneity in formulation of guidelines on the use of DMARDs in pregnancy. Recommendations for csDMARDs were similar between guidelines. There was significant variability in recommendations for b/tsDMARD use, reflecting current minimal literature in this area."

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Lupus • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Systemic Lupus Erythematosus

Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update. (PubMed, Pharmacol Res) - "Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis)...The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85..."

FDA event • Journal • Review • Alopecia • Atopic Dermatitis • Brain Cancer • Chronic Myeloid Leukemia • CNS Tumor • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Glioma • Hematological Malignancies • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Leukemia • Lung Cancer • Neurofibromatosis • Non Small Cell Lung Cancer • Oncology • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Solid Tumor • Ulcerative Colitis • MAP2K1

AbbVie Reports First-Quarter 2025 Financial Results (PRNewswire) - "Global net revenues from the immunology portfolio were $6.264 billion, an increase of 16.6 percent on a reported basis, or 18.1 percent on an operational basis. Global Skyrizi net revenues were $3.425 billion, an increase of 70.5 percent on a reported basis, or 72.0 percent on an operational basis. Global Rinvoq net revenues were $1.718 billion, an increase of 57.2 percent on a reported basis, or 59.7 percent on an operational basis. Global Humira net revenues were $1.121 billion, a decrease of 50.6 percent on a reported basis, or 49.5 percent on an operational basis."

Sales • Ankylosing Spondylitis • Crohn's disease • Hidradenitis Suppurativa • Idiopathic Arthritis • Inflammatory Bowel Disease • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Re-HU-TREAT: Replication of the Heads Up Atopic Dermatitis Trial With Registry Data (clinicaltrials.gov) - P=N/A | N=240 | Active, not recruiting | Sponsor: Technische Universität Dresden

Head-to-Head • New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis and associated colitis (EASL 2025) - "Tofacitinib (selective Janus Kinase [JAK] 1/3 inhibitor [i]), approved for the treatment of ulcerative colitis (UC), led to an improvement in colitis activity in the majority of PSC-IBD patients. Updacitinib led to a decreased activity of PSC-associated IBD and a non-significant decrease in serum ALP levels. Additional studies are warranted to monitor safety of JAK inhibition in PSC."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Respiratory Diseases • Ulcerative Colitis

Are Jak Inhibitors Contributing to Ototoxicity? Investigating Their Role in Aminoglycoside-Induced Damage (COSM 2025) - "C57BL/6J Cdh23-corrected mice were treated with JAK inhibitors (momelotinib 20 mg/kg, tofacitinib 20 mg/kg, upadacitinib 10 mg/kg) via oral gavage for 14 days, alone or combined with kanamycin (600 mg/kg, S.C.). Systemic administration of JAK inhibitors enhances the ototoxic effects of kanamycin, emphasizing the role of the JAK-STAT pathway in auditory protection. JAK2 knockout mice were particularly vulnerable to aminoglycoside-induced hearing loss and vestibular dysfunction. These findings highlight a critical role for JAK-STAT signaling in mitigating aminoglycoside ototoxicity, suggesting that patients treated with JAK inhibitors could be at higher risk for hearing loss when exposed to aminoglycosides."

Otorhinolaryngology • CDH23 • JAK2 • PAX2

Case Report: Successful Remission With Upadacitinib in Behçet's Syndrome Following a History of PFAPA Syndrome. (PubMed, Int J Rheum Dis) - "The patient was refractory to adalimumab and achieved remission after upadacitinib therapy. Genetic similarities have been reported between PFAPA syndrome and BS, involving genes such as IL-10 and IL-12A. Since the IL-10, IL-12, and IL-23 pathways can be blocked by JAK inhibitors, JAK inhibition therapy may be a potentially effective treatment option for Behçet's syndrome in a patient with a history of PFAPA syndrome."

Journal • Dental Disorders • Gene Therapies • Infectious Disease • Musculoskeletal Pain • Oncology • Pain • Rare Diseases • Stomatitis • Vasculitis • IL10 • IL12A • IL23A

Triple Biologic Therapy for Refractory Crohn's Disease. (PubMed, J Crohns Colitis) - "Triple biologic therapy remains experimental and should be approached with caution, pending more robust evidence. Larger and translational studies are needed to better identify patients who may benefit, define optimal combinations, and clarify long-term safety of these combinations."

Journal • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis

Upadacitinib Drug Survival in the Management of Patients With Moderate to Severe Atopic Dermatitis: Real-Time Data From the Biogrid Database Registry. (PubMed, Australas J Dermatol) - "These findings indicate that Upadacitinib may offer a longer-lasting treatment option with good overall retention in ad management. Real-world data such as these provide crucial insights for dermatologists in choosing appropriate therapies, potentially enhancing patient satisfaction, adherence, and long-term outcomes. Further studies with larger sample sizes and diverse populations are recommended to validate these findings and guide treatment strategies."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis. (PubMed, Front Med (Lausanne)) - "Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors (abrocitinib, upadacitinib). Prospero registration code: [392093]. PROSPERO, Centre for Reviews and Dissemination: CRD42023392093."

Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Respiratory Diseases

Upadacitinib Monotherapy After Tofacitinib Failure Was Successful for Induction But Not Maintenance of Remission in Medically Refractory Ulcerative Colitis. (PubMed, ACG Case Rep J) - "This small case series represents real-world experience of the efficacy of upadacitinib after prior tofacitinib failure in medically refractory ulcerative colitis and challenges current observations that upadacitinib is effective after tofacitinib exposure. Although all patients had a clinical or partial response after upadacitinib induction, 4/4 (100%) patients relapsed or required rescue therapy during maintenance, in contrast to previous publications."

Journal • Monotherapy • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Effectiveness and Safety of Upadacitinib in Adults Older Than 50 Years With Moderate-To-Severe Atopic Dermatitis: A Multicenter Study. (PubMed, Int J Dermatol) - No abstract available

Clinical • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A 3-Year Follow-Up of Severe Atopic Dermatitis and Atopic Keratoconjunctivitis Treated with Upadacitinib (EAACI 2025) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Immunology

Upadacitinib effective for GCA in phase III trial. (PubMed, Nat Rev Rheumatol) - No abstract available

Journal • P3 data

IFN-γ-Induced intestinal epithelial cell-type-specific programmed cell death: PANoptosis and its modulation in Crohn's disease. (PubMed, Front Immunol) - "Individual PCD inhibitors were insufficient to block IFN-γ-induced cytotoxicity, whereas the selective JAK1 inhibitor (upadacitinib) effectively blocked IFN-γ-induced cytotoxicity and PANoptosis. Furthermore, PANoptosis was significantly activated in surgically resected tissues and in publicly available single-cell RNA-sequencing datasets of intestinal tissues from patients with CD. IFN-γ induces PANoptosis in enterocytes, which can be treated with a selective JAK1 inhibitor in patients with CD."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IFNG

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study (clinicaltrials.gov) - P3 | N=348 | Not yet recruiting | Sponsor: Douglas D. Fraser

New P3 trial • Novel Coronavirus Disease

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Incidences of Herpes Zoster and Acne by Age in Japanese Patients With Atopic Dermatitis During Treatment With Baricitinib or Upadacitinib: A Single-Centre Retrospective Study. (PubMed, Exp Dermatol) - No abstract available

Journal • Retrospective data • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Herpes Zoster • Immunology • Varicella Zoster

Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply. (PubMed, Aliment Pharmacol Ther) - No abstract available

HEOR • Journal • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. (PubMed, Front Med (Lausanne)) - "This observational retrospective study involves RA patients receiving tofacitinib, baricitinib, upadacitinib, or filgotinib between September 2017 and January 2025. Factors not related to the achievement of the T2T goal at 6 months of JAK inhibitor treatment include: age, female sex, body mass index, RA disease duration, seropositivity for rheumatoid factor, seropositivity for anti-cyclic citrullinated peptides, JAK inhibitor selectivity, type and number of prior biologic treatments, concomitant use and number of prior conventional synthetic disease-modifying antirheumatic drugs, and number of prior JAK inhibitors. These conclusions are derived from a retrospective real-world study and should be confirmed in prospective studies."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? (PubMed, Aliment Pharmacol Ther) - No abstract available

HEOR • Journal • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. (PubMed, J Clin Med) - "Ninety-four percent of patients had previously failed biologics or Janus kinase inhibitors (JAKi), including 53.2% with tofacitinib. The incidence rates of colectomy, serious adverse events, and herpes zoster were 13.3, 2.3, and 1.7 per 100 patient-years, respectively. This meta-analysis confirms the effectiveness and safety of upadacitinib in a highly treatment-refractory population of UC patients."

Journal • Real-world evidence • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study. (PubMed, Arthritis Res Ther) - P | "UPA demonstrated real-world effectiveness in moderate-to-severe RA, with approximately half of patients achieving DAS28(CRP) remission at 6 months and most maintaining remission through 12 months. The real-world benefit-risk profile of UPA remains favorable and is consistent with phase 3 clinical trial data."

Journal • Observational data • Real-world evidence • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Varicella Zoster • CRP

Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis. (PubMed, Rheumatol Ther) - "A Bayesian network meta-analysis was conducted to examine the radiographic and clinical efficacy of the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, upadacitinib, and filgotinib and the biologic disease-modifying antirheumatic drug (bDMARD) adalimumab (all given with methotrexate [MTX]) in patients with rheumatoid arthritis (RA) and an inadequate response to MTX (MTX-IR). Varying treatments had the highest probability of achieving other efficacy outcomes of interest at 12, 24/26, and 48/52 weeks. In the absence of head-to-head comparisons, this analysis provides valuable evidence for the role of filgotinib in the treatment of patients with MTX-IR RA."

Journal • Retrospective data • Review • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Upadacinib for the Treatment of Refractory Morphea. (PubMed, Australas J Dermatol) - No abstract available

Journal • Dermatology • Inflammation